Translational-Omics in Aortic Stenosis (TOmAS) Biobank

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY

The objective of the TOmAS Biobank is the conservation of biological material (plasma, saliva, and tissue explanted during surgery), genetic material (DNA, RNA, etc.), and clinical data (material/data) collected from patients with cardiovascular diseases (CVD) as well as from control participants, in order to allow future studies evaluating novel proteomic, transcriptomic and epigenomic markers (as well as other emerging -omic technologies) for CVD (i.e. aortic stenosis, cardiomyopathy, myorcardial infarction, etc). The study of physiological and genetic factors will allow for the discovery of new genomic and other -omic (including proteomic, transcriptomic and epigenomic) biomarkers associated with CVD which will lead to an improved understanding of the underlying biology of CVD and may provide future insights into the prevention and treatment of this type of disease.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Healthy Volunteers: t
View:

• CVD diagnosis including, but not limited to: Aortic Stenosis, Coronary Heart Disease, Heart Failure, Atrial Fibrilation, Dilated Cardiomyopathy, Myocardial Infarction, and Spontaneous Coronary Artery Dissection.

• Undergoing cardiac surgery for non-aortic valve pathology

Locations
Other Locations
Canada
Montreal General Hospital
RECRUITING
Montreal
Royal Victoria Hospital
RECRUITING
Montreal
Contact Information
Primary
George Thanassoulis, MD
george.thanassoulis@mcgill.ca
5149341934
Backup
Mireille Roy-Joncas, RN
mireille.roy-joncas@muhc.mcgill.ca
5149341934
Time Frame
Start Date: 2017-10-12
Estimated Completion Date: 2040-01-01
Participants
Target number of participants: 10000
Treatments
CVD Group
CVD diagnosis including, but not limited to: Aortic Stenosis, Coronary Heart Disease, Heart Failure, Atrial Fibrilation, Dilated Cardiomyopathy, Myocardial Infarction, and Spontaneous Coronary Artery Dissection.
Control Group
control groups will be defined as:~1. No echocardiographic evidence of AS (or any aortic valve abnormality) and~2. 60 years of age
Related Therapeutic Areas
Sponsors
Leads: McGill University Health Centre/Research Institute of the McGill University Health Centre

This content was sourced from clinicaltrials.gov